| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
07-25-2017, 01:50 AM
|
#1 | ||
|
|||
|
News Gatherer
Community Support Team
|
Endpoints News Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson's program for $1.1B Endpoints News The Japanese pharma company agreed to pay $1.1 billion for the biotech, which has been developing a lead program for continued dosing of levodopa/carbidopa for Parkinson's patients. That's $39 a share, or a 79% premium over the unaffected early June ... Mitsubishi Tanabe to Buy Parkinson's Disease Drugs Firm NeuroDerm for $1.1BGenetic Engineering & Biotechnology News Mitsubishi Tanabe Coughs Up $1.1 Billion Cash for Parkinson's Biotech NeuroDermPharmaLive (press release) (subscription) Why NeuroDerm Ltd Acquired a Higher Price TodayMadison.com PMLiVE -Medical Xpress -The Jewish Press - JewishPress.com all 33 news articles » More... |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Mitsubishi Tanabe to Buy Parkinson's Disease Drugs Firm NeuroDerm for $1.1B - Genetic | Parkinson's News | |||
| Mitsubishi Bags ALS Approval Without Radical Benefit | ALS News & Research | |||
| Sunovion pays $624M for Canada's Cynapsus, lead PhIII Parkinson's med - FierceBiotech | Parkinson's News | |||
| inhaled l-dopa Civitas nails $55M venture round for a PhIII Parkinson's study | Parkinson's Disease | |||
Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson's program for $1.1B - Endpoi
Linear Mode
